AstraZeneca Tagrisso, Pfizer Xalkori Stand Out Among US FDA’s Single-Arm Oncology Approvals, JAMA Suggests

 
• By Bridget Silverman

Only two US approvals based on single-arm trials met the European Society for Medical Oncology’s threshold for substantial clinical benefit, according to an analysis of cancer drugs approved over a decade.

Photo of an Asian male exercising with dumbbells and doing a single shoulder press over dark background.
How strong can the data in a single arm be?

More from Clinical Trials

More from R&D